Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALA-1000 (Alar Pharmaceuticals Inc.)
- Development stage
- Unknown
- Lead developer
- Alar Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
ALA-1000 is a long-acting injectable (LAI) subcutaneous depot formulation of buprenorphine developed by Alar Pharmaceuticals for the treatment of opioid use disorder (OUD). It is designed as a sustained-release prodrug that provides therapeutically effective plasma levels of buprenorphine for at least three months, potentially reducing dosing frequency to four times per year. The formulation utilizes Alar's proprietary depot technology, which features a low-viscosity solution and small injection volume. In October 2023, Indivior acquired the exclusive global rights (excluding China, Hong Kong, Taiwan, and Macau) to develop and commercialize ALA-1000. The drug has completed Phase 2 clinical trials and is intended to follow the 505(b)(2) regulatory pathway for approval.
- Other names
- buprenorphine depotlong-acting injectable buprenorphine
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on ALA-1000 (Alar Pharmaceuticals Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALA-1000 (Alar Pharmaceuticals Inc.).